Author's response to reviews

Title: Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma

Authors:

Ju Gao (gaoju651220@126.com)
Minzhi Yin (mzhiyin@hotmail.com)
Yiping Zhu (zhuyiping918@yahoo.com.cn)
Ling Gu (guling00@163.com)
Yanle Zhang (zhangyanle123@126.com)
Qiang Li (lqcm2000@yahoo.com.cn)
Cangsong Jia (jiacangsong@sina.com)
Zhiui Ma (ma_zg@yahoo.com)

Version: 5 Date: 4 August 2013

Dear Editor,

This is the revised version of my manuscript: MS: 1164879442912124 - Activation of nucleophosmin-anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma and its correlation with the clinicopathologic variables. I have revised my manuscript according to the reviewers' comments. In this revised version, we added some mechanistic study on the tumorigenic function of ALK fusion kinase and the therapeutic significance of targeting the AKT/mTOR pathway. I have changed the title to Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma. Also I have made some changes in my abstract.

Language corrections have been done thoroughly throughout the whole manuscript. I have asked a native English speaker who is professional in molecular pathology to go over my manuscript and make the corrections. The reviewers' concerns have been addressed carefully in the Response Letter. All the changes made in this version were highlighted in red color.

The consent statement and the ethics statement has been added in the Methods section.

Thank you very much!

Zhigui Ma, M.D.

Department of Pediatrics